Ipsen SA was facing an uphill battle last month at the Endocrinologic & Metabolism Drugs Advisory Committee's review of palovarotene for a rare bone tissue condition.
Key Takeways
-
Ipsen didn’t follow FDA’s advice and conduct a placebo-controlled trial, and the study ended up failing.
The company is seeking approval of the drug for treatment of heterotopic ossification (HO) in adults and children with fibrodysplasia...





